The rate of radiographic progression-free survival at @ months was @ % among patients treated with enzalutamide , as compared with @ % among patients receiving placebo ( @ % risk reduction ; hazard ratio in the enzalutamide group , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P < @ ) .